Skip to main content

and
  1. Article

    Open Access

    PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

    Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of...

    M Puhr, J Hoefer, A Eigentler, D Dietrich, G van Leenders, B Uhl, M Hoogland in Oncogene (2016)